Suppr超能文献

超声及纤维化无创标志物用于识别肝硬化患者的准确性。

Accuracy of ultrasound and noninvasive markers of fibrosis to identify patients with cirrhosis.

作者信息

Martin Jason, Khatri Gaurav, Gopal Purva, Singal Amit G

机构信息

Department of Internal Medicine, UT Southwestern Medical Center and Parkland Health Hospital System, Dallas, TX, USA.

出版信息

Dig Dis Sci. 2015 Jun;60(6):1841-7. doi: 10.1007/s10620-015-3531-1. Epub 2015 Jan 14.

Abstract

BACKGROUND

Accurate identification of patients with cirrhosis using noninvasive markers of fibrosis is useful for esophageal varices and hepatocellular carcinoma surveillance programs. The aims of our study were to characterize the accuracy of ultrasonography, AST-to-platelet ratio index (APRI), and FIB-4 as noninvasive markers to identify the presence of cirrhosis.

METHODS

We conducted a retrospective cohort study of patients who underwent liver biopsy at a large urban safety-net institution between November 2008 and July 2011. The sensitivity, specificity, positive predictive value (PPV), negative predictive value, and overall accuracy using receiver operator characteristic curve analysis for the detection of cirrhosis were calculated for each noninvasive marker.

RESULTS

Liver biopsy was performed in 388 patients, of whom 93 (24.0 %) had cirrhosis. C-statistics for APRI and FIB-4 predicting the presence of cirrhosis were 0.68 (95 % CI 0.63-0.74) and 0.73 (95 % CI 0.68-0.78), respectively. The c-statistic for a nodular appearance on ultrasound was 0.78 (95 % CI 0.72-0.83). The PPV of a shrunken nodular-appearing liver was 64.8 %; however, PPV was significantly higher in the subset with a cirrhotic-appearing liver and signs of portal hypertension (PPV 83.6 %, p = 0.01) as well as in the subset with a noninvasive fibrosis marker also suggesting cirrhosis (PPV 77.8 %, p < 0.001).

CONCLUSION

Serum and imaging noninvasive markers of fibrosis may have insufficient accuracy when used in isolation; however, a combination of markers may allow sufficient accuracy to systematically identify patients with cirrhosis.

摘要

背景

使用纤维化的非侵入性标志物准确识别肝硬化患者,对于食管静脉曲张和肝细胞癌监测计划很有用。我们研究的目的是将超声、AST与血小板比值指数(APRI)和FIB-4作为非侵入性标志物识别肝硬化存在的准确性进行特征描述。

方法

我们对2008年11月至2011年7月期间在一家大型城市安全网机构接受肝活检的患者进行了一项回顾性队列研究。针对每种非侵入性标志物,使用受试者操作特征曲线分析计算检测肝硬化的敏感性、特异性、阳性预测值(PPV)、阴性预测值和总体准确性。

结果

388例患者接受了肝活检,其中93例(24.0%)患有肝硬化。APRI和FIB-4预测肝硬化存在的C统计量分别为0.68(95%CI 0.63 - 0.74)和0.73(95%CI 0.68 - 0.78)。超声检查出现结节样外观的C统计量为0.78(95%CI 0.72 - 0.83)。肝脏呈萎缩结节样外观的PPV为64.8%;然而,在具有肝硬化样外观和门静脉高压体征的亚组中PPV显著更高(PPV 83.6%,p = 0.01),以及在非侵入性纤维化标志物也提示肝硬化的亚组中PPV也显著更高(PPV 77.8%,p < 0.001)。

结论

单独使用时,血清和影像学纤维化非侵入性标志物的准确性可能不足;然而,标志物组合可能具有足够的准确性来系统地识别肝硬化患者。

相似文献

引用本文的文献

1
[Not Available].[无可用内容]
Adv Lab Med. 2024 Feb 14;5(2):131-147. doi: 10.1515/almed-2023-0172. eCollection 2024 Jun.
2
Serum biomarkers for liver fibrosis assessment.用于肝纤维化评估的血清生物标志物。
Adv Lab Med. 2023 Nov 14;5(2):115-130. doi: 10.1515/almed-2023-0081. eCollection 2024 Jun.

本文引用的文献

1
Non-invasive diagnosis of advanced fibrosis and cirrhosis.晚期纤维化和肝硬化的非侵入性诊断
World J Gastroenterol. 2014 Dec 7;20(45):16820-30. doi: 10.3748/wjg.v20.i45.16820.
4
Magnetic resonance imaging in cirrhosis: what's new?肝硬化的磁共振成像:有哪些新进展?
Top Magn Reson Imaging. 2014 Apr;23(2):129-49. doi: 10.1097/RMR.0000000000000017.
6
Failure rates in the hepatocellular carcinoma surveillance process.肝癌监测过程中的失败率。
Cancer Prev Res (Phila). 2012 Sep;5(9):1124-30. doi: 10.1158/1940-6207.CAPR-12-0046. Epub 2012 Jul 30.
9
Effectiveness of hepatocellular carcinoma surveillance in patients with cirrhosis.肝硬化患者肝癌监测的效果。
Cancer Epidemiol Biomarkers Prev. 2012 May;21(5):793-9. doi: 10.1158/1055-9965.EPI-11-1005. Epub 2012 Feb 28.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验